School of Pharmaceutical Sciences, USM
Academic Session 2010/2011
NAME : LIM KOK HAN
I/C NO : 881114-03-5379
MATRIC NO : 95298
GROUP : B
Lecturers: Prof. Madya Dr. Azmi Sarriff
FORM 1- Prescription’s Intervention Documentation Form
Student name ( No. ID ) : LIM KOK HAN ( 95298)
Clerkship Group : B
1. Prescription Data (1- counseling part)
Pt.’s Name :ABC Date : 7/6/2010
Age (years ) : 59
Gender : Male Female
Wts (Kg) : not available Ht.(cm) -
Allergy : not available
Diagnosis : Diabetes Mellitus Type 2
1) Tablet hydrocortisone 10mg OD/5 mg ON
2) S/C Humulin N 18unit ON
3) Tablet Glucovance (500/5) II/II BD 4/12
4) Tablet L-tyroxine 150 mg OD
5) Tablet Epilim 400 mg BD
6) Tablet Glyprin I/I OD
7) Tablet Lovastatin 40 mg OD
2.Prescription Writing Error ( check all that apply )
Incomplete Rx (omission error )
Unclear quantity prescribed
Calculation error/decimal point
Others : use of brand name instead of generic name
Brief Description: this prescription’s writing is satisfactory, with the name of the drug, dose, frequency and duration of therapy were written clearly. But however, the use of brand name in the prescription, instead of generic name is still a common issue . For example, in this prescription, the use of brand name can be seen with the prescribed medication called tablet epilim® (which is sodium valproate) ; glyprin® (which is a combination of aspirin 100mg and glycine 45mg) and glucovance® ( a combination of metformin and glyburide).
2. Prescription-related Problems ( check all that apply )
Drug without indication
Indication without drug
Dose too high
Dose too low
Unavailable dosage form
Wrong/inappropriate dosing frequency
Risk for adverse drug reactions
Others : uncertainty of dose of L-thyroxine used
Brief Description: the normal recommended maintenance dose of L-thyroxine for hypothyroidism is about 100-125mcg/daily. The dose ordered was 150 mcg daily, which is a bit higher than the recommended dose. However this dose may be used in long standing, severe hypothyroidism.
There are some drug-drug interaction that might occur:
MANAGEMENT:Small single doses of salicylates are unlikely to cause significant effects. However, patients who take large doses of salicylates or over a prolonged period of time should be closely monitored for clinical and laboratory evidence of valproate toxicity and hepatotoxicity. Patients should be advised to notify their physician if they experience possible symptoms of toxicity (e.g., malaise, weakness, lethargy, drowsiness, nausea, vomiting, or abdominal pain).
MANAGEMENT: Close clinical monitoring of glycemic control is recommended if these drugs are coadministered with antidiabetic agents. Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen. Dose adjustments of the hypoglycemic agent may be required
3) hydrocortisone ↔ insulin isophane(Humulin N) : long term use of corticosteroid is associated with increased in blood glucose level, thus may reduce the effect of insulin given
MANAGEMENT:Close clinical monitoring of glycemic control is recommended if these drugs are coadministered with antidiabetic agents. Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen. Dose adjustments of the hypoglycemic agent may be required.
4) aspirin ↔ insulin isophane : The hypoglycemic effect of insulin may be potentiated by asprin, thus increase risk of hypoglycemia
MANAGEMENT: Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be advised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.
3. Intervention ( discussed – recommendation & clinical
From the prescription record, no intervention had been made on this prescription. But, however, due to the concern of drug-drug interaction due to multiple drug use and complexity of regimen, the pharmacist need to be aware of potential interaction that might occur (as discussed above) and dosage adjustment or other intervention might need to be considered. The use of certain agent might titrated based on weigh benefit: risk ratio and the significance of the problems that might developed from the prescribed drugs.
EXAMPLE OF SOME COUSELLING FORM:
*here is an example of what counseling points need to be delivered to the patient regarding her medication
General counseling guidelines:
Begin with introduce ourself and identify the patient by name.
1. Ask patient if it is a convenient time to discuss their medications.
2. Explain the importance of discussing their medications.
3. Verify what medications they are taking, known disease states, drug allergies, and so on.
4. Ask what they know about the medication and their illness.
5. Tell patient the name (brand and generic) of medication, dosage, frequency, and route of administration.
6. Explain how long it will take for the medication to show an effect.
7. Emphasize the benefits of the medication.
8. Describe potential side effects (common and serious).
a. Tell patient what signs to look for.
b. Recommend ways to minimize side effects or identify if the side effects will go away.
· Explain the use of this medicine in this patient, the dose and frequency.
· Advise patient to take oral medication with food to minimize GI upset. Warn patient not to stop taking drug abruptly.
· Caution diabetic patients that insulin or oral hypoglycemic agent needs may increase.
· Instruct elderly patient to have blood pressure, blood glucose, and electrolytes monitored regularly
· Advise on some common side effect of this drug (for example: weight gain, increased BP,GI irritation if not taken with food, etc) and how to handle if these side effects become troublesome
· Advice patient how to do if a dose is missed
2) Humulin N and Glucovance( Metformin + Glyburide)
· Teach name, dose, action, and common side effects of insulin.
· Emphasize on the importance of compliance to this medicine in controlling the blood glucose level
· Teach some common sign/symptoms of hypoglycemia, and how to handle them if these side effects become troublesome
· If the patient is a new patient, teach patient how to use/inject Humulin N properly and make sure patient understand each direction given.
· Also need to emphasize the patient on the importance of non-pharmacological approach as adjunct treatment to the antidiabetic agents (healthy diet, exercise, no smoking/alcohol, weigh reduction, etc)
Explain the use/indication of this medicine, how it works, dose should be taken and the dosing frequency
· Advise patient to take medication with evening meal if possible.
· Explain importance of adhering to low-cholesterol, low-fat diet during treatment. Suggest consultation with nutritionist as needed.
· Instruct patient to report the following symptoms to health care provider: unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.
· Caution patient to avoid or decrease alcohol intake.
· Advise patient not to take any additional medications or supplementation without approval by health care provider.
· Emphasize importance of returning for follow-up liver function and blood cholesterol tests as instructed.
· Explain that this treatment must be continued over years.
4) epilim® (aspirin)
FORM 1- Prescription’s Intervention Documentation Form
Student name ( No. ID ) :LIM KOK HAN (95298)
Clerkship Group: B
1. Prescription Data ( For dispensing purpose)
Pt.’s Name ABC Date : 29/6/2010
Age (years ) : 70
Gender : Male Female
Wts (Kg) : - Ht.(cm) -
Allergy : not known
Diagnosis : Diabetes Mellitus, Hypertension, Ischemic Heart Disease
1. Tablet simvastatin 20 mg ON
2. Tablet Glucovance (500/2.5) I/I O
3. Lasix ® 80 mg BD
4. Vasteral® 20 mg BD
5. Duride® 60 mg OD
6. Glyprin® I/I OD
7. Perindopril 8mg OD
8. Spironolactone 25 mg OD
9. Gemfibrozil 60mg bd
10.Amlodipine 10 mg OD
11.Kalimate powder 5 mcg TDS .
a. Prescription Writing Error ( check all that apply )
ii.Incomplete Rx (omission error )
iv.Unclear quantity prescribed
vii.Calculation error/decimal point
Brief Description :
- Since there are too many drugs prescribed, the handwriting of the prescriber sometimes not clear and illegible to read.
- Some drugs ordered were written as brand name instead of generic name , for example Duride® (Isosorbide mononitrate), Glyprin®(aspirin+glycine), Glucovance®( metformin+glyburide), and vasteral®(trimetazidine)
- The quantitiy prescribed and frequency of use of some drug also not clears. For example the writing of unit mg and µg can be confusing due to illegible handwriting. Frequency and duration of therapy of certain medications also not written clearly.
b. Prescription-related Problems ( check all that apply )
i.Drug without indication
ii.Indication without drug
iii.Dose too high
iv.Dose too low
v.Unavailable dosage form
vi.Wrong/inappropriate dosing frequency
xiii.Risk for adverse drug reactions
1) Wrong/inappropriate dosing frequency
- The presciber ordered 1 tablet Glucovance( 500 metformin+5 glyburide) OD, but the standard reference recommend the the glucovance should be given 1 tablet BD for the most effective outcome.
2) Inappropriate dosage and dosing frrequecy of gemfibrozil which was prescribed 60mg OD. From the standard reference, the dose and frequency prescribed is inappropriate. The recommended dose is 600 mg BD(max: 1.5g/day)
3) Drug-drug interactions and risk of ADR:
Since this patient was on many medications (11 medications), there is high risk for drug-drug interaction and also the risk for adverse drug reaction.
Some drug-drug interaction has been detected:
Major Interaction: between 2 antilipidemic drugs given (gemfibrozil and simvastatin)àsevere myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, etc. High levels of plasma simvastatin are associated with an increased risk of musculoskeletal toxicity.
MANAGEMENT: Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. If the combination is prescribed, a fibrate other than gemfibrozil may be preferable, along with lower initial dosages of the HMG-CoA reductase inhibitor. If gemfibrozil is used, simvastatin and rosuvastatin daily dosage should not exceed 10 mg.
Other interactions that might occur:
-furosemide + glucovance àThe efficacy of oral hypoglycemic agents may be diminished by furosemide
-glucovance + gemfibrozil/aspirinàThe hypoglycemic effect of glucovance(metformin+glyburide) may be potentiated by gemfibrozil or/and aspirin
General management:Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage may require dosing adjustment if an interaction is suspected. Patients should be advised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic controlwhen these drugs are withdrawn.
c. Intervention ( discussed – recommendation & clinical
The pharmacist had contact the prescriber (the doctor) and recommends the intervention for the detected drug related problems in this patient’s prescription, which include:
- The dosing rate(frequency) of glucovance(metformin+glyburide) had been changed from 1 tablet OD to 1 tablet BD
- Dose and dosing frequency of gemfibrozil had been changed from 60 mg BD( which is low dose) to 300 mg OD
Other than the above interventions, there are no other interventions made by the pharmacist in charged for this prescription.
In my opinion,
However, the pharmacist needs to be aware of the potential interactions that might occur among the drugs given. Some interactions can be of clinical significance and affect the patient’s outcome. For example the use of simvastatin and gemfibrozil together could increase the risk of myopathy, thus this problem might need to be intervened wisely based on clinical knowledge. Consider dosage/dosing interval adjustment for both drug if the combination is required(weigh benefit risk ratio) or may consider other alternative agent that pose less problem.If the combination is required in this patient, a fibrate other than gemfibrozil may be preferable, along with lower initial dosages of the HMG-CoA reductase inhibitor. If gemfibrozil is used, simvastatin daily dosage should not exceed 10 mg. Monitoring the efficacy (based on lab data assessment) and toxicity (adverse drug effect/side effects as reported by patient) of this combination thus is required.
Last Updated on Sunday, 11 September 2011 18:59
MD HASHIMIE BADDRUDIN BIN MAT HASSAN (95304)
LIM KOK HAN (95298)
Lecturer : Prof. Madya Dr. Azmi Sarriff
1. Be prepared to counsel a patient about a new prescription for budesonide inhaler medication
Mr. Abu is a 29-years-old patient which is a regular client and present with the attached new prescription. The techniques apply during the counseling are:
Some important point to remember:
First, identify who is our patient-geriatric? Pregnant women?, etc. Then we should
1. Establish a relationship with the patient and to develop trust.
2. Demonstrate concern and care for the patient.
3. Help the patient manage and adapt to their illness.
4. Help the patient manage and adapt to their medication(s).
5. Identify and minimize factors that may contribute to noncompliance.
6. Empower the patient to be an active participant in their health care.
PRIME QUESTION TECHNIQUE is applied to counsel a patient about a new prescription of budesonide inhaler
1)What did your doctor tell you the medication is for?
Access the patient’s understanding on drug therapy by first asking the patient if he knows the indication of the medication prescribed to him and why he needs to take the medication. For example what is the use of budesonide inhaler? Why you need to take this? Pharmacist should support any lacking of information given by the patient to make sure patient always get the right information. In this case, this patient is already on terbutaline inhaler, so a SHOW and TELL technique might be useful be applied to access how good is the patient use the inhaler. Thru this way,we evaluate how the patient administer the medication. If it is wrong, then must ready to teach the patient the proper way how to use inhaler.
2)How did your doctor tell you to take the medication?
Ask the patient how often, how much and how long he should be taking the medication. For example in this situation we use budesonide inhaler (200µg); 1 or 2 puffs twice daily. Use the show and tell technique, ask the patient to show how to use the inhaler if the patient not able or done the error, pharmacist should show/guide the patient with the proper technique and information. So the pharmacist must know the proper way of using inhaler so that he/she can really counsel the patient on this. Emphasize the patient should not take the double dose when his miss the dose but try to take as soon as possible if his remember and proceed with normal dose if the dose interval is quite close with the next dose. Explain about the proper storage of medication. Suggest that inhaler should be always bringing together wherever he/she goes and protect the medicine from heat exposure.
3) What did your doctor tell you to expect from this medication?
Clarify with the patient his expectation toward the treatment which include the beneficial effect that he supposed to expect, for example relieve the asthmatic symptoms. Ask him how to ascertain the medication is working or not for example if the symptom is not relieve after taking the medication, this may associated with the way he uses the inhaler
(inaccurate dose) or might need special intervention from physician.
Tell the common side effect of the medications he is taking, and how to handle them. For example, the most common budesonide side effects are headache, nausea, respiratory infection, mild cough or wheezing. If the bad reaction occurs advise patient to refer/report to the physician or pharmacist.
Then, at end of counseling session, don’t forget to do final verification by verifying the patient if he/she has fully understood what had explained, if possible ask them to repeat what had been explained by pharmacist or ask them some question regarding medication use and pharmacist should correct the mistakes and add-in the missing information.
2) What concerns might a patient have about a new diagnosis of asthma?
Based on the case given to us,
This patient was a bit worried about his new diagnosis as he is still young (29 year old) and he doesn’t want to end up his life like her aunty who has emphysema and on oxygen
He was curious about his current condition as he was referred to specialist and was prescribed with a new medication. So this patient might become more worried about the severity of his condition.
Besides, the patient also reported the increased troublesome of the asthmatic condition. He has wheezing and increased in coughing at night and has difficulty in breathing. From these complaints, the patient might think that his health is worsening. He also might have concern on the additional side effects of the new medication given, added to this concurrent medications.
So to conclude, the patient become more worried about his new diagnosis of asthma and feel that the increased symptoms he experienced had affect his quality of life a lot. He became worried if the new asthmatic condition will make his condition worse. The illness he had he might think become more and more severe.
In general,Individuals with persistent asthma have a higher incidence of both anxiety and depression than those without chronic disease. Many of these individuals do not follow or are not capable of following the recommended treatment plans
3) What information and skills will the patient need to manage her condition?
Information and skills the patient includes the following:
-Basic facts about asthma-including the risk factors that may exacerbate the conditions, the contrast between asthmatic and normal airways; whathappens to the airways in asthma attack
-Roles of medications
The patient should know, in general, how the medications work
• Long-term control: medications that prevent symptoms, often by reducing inflammation
• Quick relief: short-acting bronchodilator (terbutaline) relaxes muscles around airways
Stress the importance of long-term-control medications and not to expect quick relief from them.
-Skills: access the correct use of aerosol delivery devices and show the proper way of using/handling inhaler to ensure the optimal delivery and efficacy of the medication.
Inhaler use (ask patient to demonstrate). For example,in this case, the patient is now on 2 inhalers—for rescue and longterm control. Since a bronchodilator (terbutaline) and maintenance medications (budesonide) were prescribed, the patient needs to use the bronchodilator first, wait 5 minutes, and then use the maintenance inhaler.
Other skills needed: Spacer/holding chamber use; Symptom monitoring, peak flow monitoring,
and recognizing early signs of deterioration; and use of peak flow meter and/or symptom diary for self-monitoring
-Environmental control measures
Identifying and avoiding environmental precipitants or exposures that may precipitate the asthmatic attack
-When and how to take rescue actions
Responding to changes in asthma severity (daily self-management plan and action plan)
Explain and emphasize on the importance of compliance to medications.(what should do if a dose is missed, etc)
Pharmacist also needs to explain about the expected side effects from the medications, how to handle them and also when the patient is expected to see the beneficial effect from the therapy given. Follow up and monitoring patient progress is required to access the efficacy (improvement in signs based on patient report and lung function test)/symptoms, interaction and toxicity (adverse effect of the medications-based on patient complaints and lab data) of medications which may require new intervention.
Last Updated on Sunday, 11 September 2011 18:58
100 Top Universities
Ranking in the Field ¹
|1||Harvard University||United States|
|2||University of California, San Francisco||United States|
|3||The Johns Hopkins University||United States|
|4||University of Washington||United States|
|5||Columbia University||United States|
|6||University of California, Los Angeles||United States|
|7||The University of Texas Southwestern Medical Center at Dallas||United States|
|8||University of Michigan - Ann Arbor||United States|
|9||University of Pittsburgh||United States|
|11||University College London||United Kingdom|
|12||Stanford University||United States|
|13||University of Oxford||United Kingdom|
|14||University of Cambridge||United Kingdom|
|15||University of Minnesota, Twin Cities||United States|
|16||Mayo Medical School||United States|
|17||University of North Carolina at Chapel Hill||United States|
|18||Vanderbilt University||United States|
|19||The University of Texas M. D. Anderson Cancer Center||United States|
|20||University of Wisconsin - Madison||United States|
|21||Yale University||United States|
|22||University of Pennsylvania||United States|
|23||The Imperial College of Science, Technology and Medicine||United Kingdom|
|24||Duke University||United States|
|25||University of California, San Diego||United States|
|26||Cornell University||United States|
|27||King's College London||United Kingdom|
|27||Tufts University||United States|
|29||University of Toronto||Canada|
|30||University of Nottingham||United Kingdom|
|31||University of California, Berkeley||United States|
|32||Emory University||United States|
|33||The University of Texas Health Science Center at Houston||United States|
|35||Boston University||United States|
|37||Massachusetts Institute of Technology (MIT)||United States|
|38||University of Zurich||Switzerland|
|39||Washington University in St. Louis||United States|
|40||University of Munich||Germany|
|41||University of Melbourne||Australia|
|42||Brown University||United States|
|43||Northwestern University||United States|
|44||University of Colorado at Denver||United States|
|46||University of Basel||Switzerland|
|47||University of Amsterdam||Netherlands|
|48||University of Florida||United States|
|49||University of Rochester||United States|
|50||University of Bristol||United Kingdom|
|51-75||Baylor College of Medicine||United States|
|51-75||Case Western Reserve University||United States|
|51-75||Catholic University of Leuven||Belgium|
|51-75||Catholic University of Louvain||Belgium|
|51-75||New York University||United States|
|51-75||The University of Glasgow||United Kingdom|
|51-75||The University of Manchester||United Kingdom|
|51-75||The University of Queensland||Australia|
|51-75||The University of Texas Health Science Center at San Antonio||United States|
|51-75||The University of Tokyo||Japan|
|51-75||The University of Western Australia||Australia|
|51-75||University of Arizona||United States|
|51-75||University of Chicago||United States|
|51-75||University of Frankfurt||Germany|
|51-75||University of Gothenburg||Sweden|
|51-75||University of Heidelberg||Germany|
|51-75||University of Iowa||United States|
|51-75||University of Maryland, Baltimore||United States|
|51-75||University of Massachusetts Medical School - Worcester||United States|
|51-75||University of Milan||Italy|
|51-75||University of Southern California||United States|
|51-75||University of Utah||United States|
|51-75||VU University Amsterdam||Netherlands|
|76-100||Medical College of Wisconsin||United States|
|76-100||National Taiwan University||Taiwan|
|76-100||Pierre and Marie Curie University - Paris 6||France|
|76-100||State University of New York at Buffalo||United States|
|76-100||The George Washington University||United States|
|76-100||The University of Sheffield||United Kingdom|
|76-100||The University of Texas Medical Branch at Galveston||United States|
|76-100||Thomas Jefferson University||United States|
|76-100||University of Alberta||Canada|
|76-100||University of Barcelona||Spain|
|76-100||University of Cincinnati||United States|
|76-100||University of Copenhagen||Denmark|
|76-100||University of Freiburg||Germany|
|76-100||University of Helsinki||Finland|
|76-100||University of Illinois at Chicago||United States|
|76-100||University of Manitoba||Canada|
|76-100||University of Medicine and Dentistry New Jersey||United States|
|76-100||University of Miami||United States|
|76-100||University of Nebraska Medical Center||United States|
|76-100||University of Paris Descartes (Paris 5)||France|
|76-100||University of Sao Paulo||Brazil|
|76-100||University of Tuebingen||Germany|
|76-100||University of Virginia||United States|
|76-100||Virginia Commonwealth University||United States|
|¹ Institutions within the same rank range are listed alphabetically.|
Sources: Institute of Higher Education, Shanghai.
Last Updated on Sunday, 11 September 2011 16:12
Sumber : Berita Harian Online
TANGGAPAN umum tugas ahli farmasi hanya memberi ubat kepada pesakit sedangkan tanggungjawab Penolong Pegawai Farmasi yang ditempatkan di kaunter lebih kompleks.
FARIDAH (dua dari kanan) memberi penerangan prosedur pemberian ubat kepada Penolong Pegawai Farmasi PPUKM.
Peranan ahli farmasi lebih tertumpu kepada terapi ubatan iaitu memastikan ubat diberikan kepada pesakit dan orang ramai selamat, berkesan dan berkualiti serta memberi maklumat seperti kebaikan dan kesan sampingannya.
Mereka bertanggungjawab melindungi pesakit daripada ubat merbahaya, iklan ubat memperdayakan dan amalan perubatan yang salah menerusi penguatkuasaan akta dan peraturan berkaitan.
Ahli farmasi juga bertanggungjawab mengenalpasti masalah pengambilan ubat pesakit dan cuba sedaya upaya mencari jalan penyelesaian kepada kesan sampingan dihadapi seperti alahan.
Ketua Jabatan merangkap Pengurus Farmasi Pusat Perubatan Universiti Kebangsaan Malaysia (PPUKM), Faridah Md Yusof, berkata antara rutin ahli farmasi adalah memberi kaunseling mengenai ubat kepada pesakit dengan menjelaskan cara pengambilan ubat yang betul, memaklumkan kesan sampingan mungkin dialami, cara penyimpanan ubat serta makanan perlu dielak apabila mengambil sesetengah ubat.
Ahli farmasi yang berkhidmat di hospital, katanya, akan turut ditempatkan di wad untuk menjalankan aktiviti farmasi klinikal termasuk memantau pengambilan ubat pesakit seperti menyaring ketepatan dos, ubat yang betul dan kekerapan pengambilan ubat yang sewajarnya.
“Mereka juga akan mendapatkan maklumat sejarah pengambilan ubat pesakit bagi memastikan tiada alahan dan memastikan pesakit tidak mencampur adukkan pengambilan ubat tradisional dengan ubat hospital kerana ia boleh mendatangkan kesan sampingan.
“Kini, aktiviti ahli farmasi juga kian berkembang apabila turut memberi perkhidmatan ‘Medication Therapy Adherence Clinic’ iaitu memberi kaunseling kepada pesakit sebelum mereka berjumpa pakar atau pegawai perubatan bagi memastikan tahap pematuhan pesakit terhadap ubat diambil,” katanya.
Faridah berkata antara tugas lain dijalankan ahli farmasi di hospital adalah membuat pembelian ubat, memastikan pesakit diberikan ubat yang betul serta memastikan proses pemberian ubat berjalan lancar iaitu masa menunggu maksimum 20 minit mengikut saranan Kementerian Kesihatan.
Beliau berkata antara cabaran dihadapi ahli farmasi kini adalah melaksanakan sepenuhnya Kempen Kenali Ubat Anda iaitu memastikan pesakit mengetahui nama ubat serta mengamalkan cara pengambilan betul termasuk dos, masa dan ubat yang betul.
“Ahli farmasi juga perlu memainkan peranan bagi meningkatkan kesedaran pengguna agar hanya mengambil ubat dari sumber boleh dipercayai seperti pegawai perubatan, klinik dan farmasi serta menghindari ubat dijual di kaki lima atau kedai runcit,” katanya.
Katanya, peluang pekerjaan ahli farmasi bukan saja di hospital, malah boleh berkhidmat di farmasi komuniti pusat beli belah, pensyarah, pengurus produk di syarikat farmaseutikal, pegawai penguat kuasa Kementerian Kesihatan serta pegawai penyelidik.
“Potensi kerjaya sebagai ahli farmasi adalah cerah kerana kerajaan kini dalam usaha mengurangkan nisbah penduduk kepada ahli farmasi daripada 1:4,335 kepada 1:2000.
“Persatuan Farmasi Malaysia juga dalam usaha mendapatkan ‘Dispensing Right’ ahli farmasi bagi membolehkan lebih banyak Farmasi Komuniti dibuka sekaligus membuka lebih banyak peluang pekerjaan bagi graduan bidang ini,” katanya.
Kelayakan akademik bagi menjadi ahli farmasi adalah Ijazah Sarjana Muda Farmasi dan antara universiti yang menawarkan program ini adalah Universiti Kebangsaan Malaysia, Universiti Malaya, Universiti Islam Antarabangsa Malaysia, Universiti Teknologi Mara serta Universiti Sains Malaysia
Last Updated on Wednesday, 12 October 2011 19:39
List of Pharmacy Shool/Faculties/Department in Malaysia that offer Bachelor of Pharmacy (B. Pharm) and Diploma of Pharmacy (D.Pharm)
1. Aimst University - Faculty of Pharmacy
Jalan Bedong - Semeling
08100, Bedong, Kedah Darul Aman
Tel: +604-429 8000
Fax: +604-429 8007/8008/8009
AIMST Dental Institute
2. Cyberjaya University College of Medical Sciences - Faculty of Pharmacy
CUCMS Main Campus
No. 3410, Jalan Teknokrat 3,
Cyber 4, 63000 Cyberjaya,
Selangor Darul Ehsan,
Tel : +603 8313 7000
Fax : +603 8313 7001FAX:
3. International Islamic University Malaysia - Kulliyyah of Pharmacy
Kulliyyah of Pharmacy
International Islamic University Malaysia
Jalan Sultan Ahmad Shah,
Bandar Indera Mahkota,
Pahang Darul Makmur,
Tel : +609-5716400
Fax : +609-5716775
4. International Medical University - Faculty of Pharmacy & Health Sciences
Bukit Jalil (Main Campus)
INTERNATIONAL MEDICAL UNIVERSITY
No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
Tel: (603) 8656 7228
Fax: (603) 8656 7229
5. Island College of Technology (ICT), Department of Pharmacy
Island College of Technology (ICT)
Sungai Rusa, 11000 Balik Pulau,
6. Management and Science University - School of Pharmacy
Management & Science University,
University Drive, Off Persiaran Olahraga,
Section 13, 40100 Shah Alam, Selangor Darul Ehsan.
Tel (603-55216868) Fax (603-55112848)
7. Segi University College - Faculty of Pharmacy & Health Sciences
8. UCSI University-Faculty of Pharmaceutical Sciences
No.1 Jalan Menara Gading,
UCSI Heights, 56000 Cheras,
W. P. Kuala Lumpur, MALAYSIA
(Tel) +603.9101.8880, (Fax) +603.9102.3606
9. Universiti Kebangsaan Malaysia - Faculty of Pharmacy
Faculty of Pharmacy,
Universiti Kebangsaan Malaysia,
Jalan Raja Muda Aziz,
50300 Kuala Lumpur, Malaysia.
Tel : 603 9289 7265 Faks : 2698 3271
10. University of Malaya - Department of Pharmacy, Faculty of Medicine
Department of Pharmacy
3rd Floor, Pharmacy and Allied Health Building
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Tel: +603–7967 4964
Fax: +603–7967 4959
11. Universiti Sains Malaysia - School of Pharmaceutical Sciences
School of Pharmaceutical Sciences
Universiti Sains Malaysia
Minden, 11800 Pulau Pinang
12. Universiti Teknologi MARA - Faculty of Pharmacy
Faculty of Pharmacy,
Level 10, FF1 Building,
Universiti Teknologi MARA,
Puncak Alam Campus,
Bandar Puncak Alam
Phone: 603-32584650, 603-32584653
13 MAHSA University College, Faculty Of Pharmacy
Mahsa University College
Jalan Universiti Campus (JUC)
Jalan Elmu, Off Jalan Universiti, 59100 Kuala Lumpur, Malaysia.
Pusat Bandar Damansara Campus (PBD)
Level 6, Block A, Pusat Bandar Damansara, Damansara Heights, 50490 Kuala Lumpur, Malaysia.
+603-7965 2555 (JUC) , +603 2092 9999 (PBD)
+603-7965 2688 (JUC) , +603 2093 1599 (PBD)
+603 2092 9999 (PBD) Ext: 879,836,863,835,834,951,952,953,954,955,804,805
Last Updated on Sunday, 11 September 2011 17:03